Low-Dose Naltrexone Cost in Pennsylvania 2026

What Low-Dose Naltrexone Actually Is

Low-dose naltrexone uses the opioid-antagonist drug naltrexone at doses well below the FDA-approved 50 mg daily threshold. The FDA approved naltrexone 50 mg for opioid use disorder and alcohol use disorder, and that label is publicly available through the FDA accessdata portal. [1] Doses between 1.5 mg and 4.5 mg are prescribed off-label for conditions including fibromyalgia, multiple sclerosis, Crohn's disease, and other inflammatory or autoimmune conditions.

How It Differs From Standard Naltrexone

Standard naltrexone blocks opioid receptors continuously at 50 mg. At doses below 5 mg, the receptor blockade is brief, typically lasting four to six hours after a nighttime dose. That brief blockade may trigger a rebound increase in endogenous opioid production and reduce pro-inflammatory microglial signaling. Younger et al. Published the foundational mechanistic hypothesis in 2009, showing in a pilot fibromyalgia trial (N=10) that 4.5 mg nightly produced a 30% reduction in pain scores versus placebo. [2]

Why the Dose Has to Be Compounded

No pharmaceutical manufacturer produces naltrexone in doses below 50 mg as an FDA-approved finished product. Because of that gap, patients need a compounding pharmacy operating under section 503A of the Federal Food, Drug, and Cosmetic Act to prepare capsules at their prescribed dose. The FDA's framework for 503A pharmacies requires a valid patient-specific prescription from a licensed prescriber. [1]

Low-Dose Naltrexone Prices in Pennsylvania in 2026

Cash-Pay Price at Compounding Pharmacies

The average cash-pay price at licensed 503A compounding pharmacies across Pennsylvania in 2026 is approximately $50 per month for a 30-day supply of oral capsules at doses between 1.5 mg and 4.5 mg. That figure holds whether the pharmacy is in Philadelphia, Pittsburgh, Allentown, or a rural county, because most Pennsylvania compounders ship statewide.

Prices vary slightly by dose and capsule count. A 90-day supply often runs $120 to $135, saving roughly $15 versus three separate monthly fills. Some pharmacies charge a one-time compounding setup fee of $10 to $15 on the first order.

Retail Pharmacy Pricing (Non-Compounded)

Standard 50 mg naltrexone tablets are available at retail pharmacies. GoodRx lists generic naltrexone 50 mg tablets at roughly $30 to $60 for a 30-day supply in Pennsylvania ZIP codes, depending on the pharmacy. [3] Those tablets cannot simply be split to achieve LDN doses reliably because naltrexone is not formulated for accurate micro-dosing from a standard tablet. Compounded capsules are the clinically appropriate route for LDN.

Price Compared to Neighboring States

Pennsylvania's $50/month cash-pay compounding price sits in line with Ohio and New Jersey, both of which average $48 to $55/month at comparable 503A pharmacies. New York City-area pharmacies trend slightly higher at $60 to $70/month, partly because of higher overhead costs. That context matters if a Pennsylvania patient considers using an out-of-state compounder that ships to PA: prices may not be meaningfully lower.

Pennsylvania Medicaid Coverage for Low-Dose Naltrexone

Pennsylvania Medicaid covers low-dose naltrexone for certain off-label indications. Coverage requires prior authorization and documentation of medical necessity.

Which Medicaid Plans Cover It

Pennsylvania's fee-for-service Medicaid program and several managed care organizations (MCOs) participating in HealthChoices, the state's Medicaid managed care program, list naltrexone on their formularies. The standard 50 mg tablet appears on most formularies at a low tier. For compounded LDN, coverage depends on the individual MCO. Clinicians must submit chart notes documenting the diagnosis, prior treatment failures, and clinical rationale.

The Pennsylvania Department of Human Services administers HealthChoices across five geographic zones. Each zone's MCO has slightly different prior-authorization criteria. Patients should call the member services number on their Medicaid card to confirm current LDN policy before filling a prescription.

Covered Indications Under PA Medicaid

Pennsylvania Medicaid has approved coverage for naltrexone in the context of opioid use disorder and alcohol use disorder per the FDA-approved indication. For off-label LDN use in fibromyalgia or autoimmune conditions, coverage is handled case by case. A 2024 systematic review published in Frontiers of Pharmacology (N=4,000+ pooled patients) found that LDN reduced pain scores across fibromyalgia and inflammatory bowel disease cohorts, data that supports medical-necessity arguments in prior-authorization letters. [4]

Physicians at the University of Pennsylvania and other academic centers in the state have successfully obtained Medicaid coverage for LDN by citing Younger's fibromyalgia trial [2] and the Raknes and Simonsen pharmacokinetic study demonstrating dose-linear absorption at low doses. [5]

What to Do If Medicaid Denies Coverage

A denial is not final. Pennsylvania law gives Medicaid enrollees the right to a fair hearing within 90 days of a denial notice. The Pennsylvania Health Law Project provides free legal assistance for Medicaid appeals and specifically lists prior-authorization denials as a covered service type. During the appeal, patients may continue using the $50/month cash-pay compounding route while the case is reviewed.

Commercial Insurance Coverage in Pennsylvania

Most commercial plans sold in Pennsylvania do not automatically cover compounded LDN because the dose is off-label and requires a specialty compounder. That does not mean coverage is impossible.

Filing a Prior-Authorization Request

A prior-authorization request for LDN should include the following: the diagnosis code (ICD-10-CM M79.7 for fibromyalgia, K50.x for Crohn's disease, or the relevant code for the patient's condition), documentation of at least two prior treatment failures, a letter of medical necessity from the prescribing clinician citing primary literature, and the pharmacy's 503A accreditation.

The Endocrine Society's clinical practice guidelines note that off-label compounded medications require documented clinical rationale. [6] That framing translates directly into stronger prior-authorization language.

When Insurance Denies the Claim

An insurer denial triggers the right to an internal appeal under the Affordable Care Act, followed by an external review by an independent organization if the internal appeal fails. Pennsylvania's Insurance Department oversees this process. External review requests must be filed within four months of the final internal denial. Given that LDN costs only $50/month out of pocket, some patients decide the appeals process is not worth the time relative to the modest cash-pay cost.

HSA and FSA Eligibility

Because LDN is a prescription medication, the out-of-pocket cost qualifies for payment through a Health Savings Account (HSA) or Flexible Spending Account (FSA). A patient in a 22% federal tax bracket who spends $600/year on LDN saves roughly $132 in taxes by routing that payment through an HSA. The IRS defines eligible medical expenses in Publication 502. [7]

Is Compounded Low-Dose Naltrexone Legal in Pennsylvania?

Yes. Compounded LDN is legal in Pennsylvania when prepared by a 503A-registered pharmacy operating under a valid patient-specific prescription from a Pennsylvania-licensed prescriber. The FDA's 503A framework, codified in 21 U.S.C. § 353a, permits pharmacies to prepare compounded drugs for individual patients. [1]

Pennsylvania State Pharmacy Board Requirements

The Pennsylvania State Board of Pharmacy licenses and inspects compounding pharmacies operating within the state. Pharmacies compounding LDN must comply with United States Pharmacopeia (USP) Chapter 795 standards for non-sterile preparations, because oral capsules are non-sterile products. USP 795 specifies beyond-use dating, environmental monitoring, and ingredient sourcing requirements. [8]

Out-of-state 503A pharmacies that ship into Pennsylvania are subject to their home state's board of pharmacy regulations and must comply with Pennsylvania's reciprocal dispensing rules. A patient receiving LDN shipped from, say, a Florida 503A pharmacy into Philadelphia is operating legally as long as the prescribing clinician holds a valid Pennsylvania license.

What "503A" Means Versus "503B"

503B pharmacies are larger outsourcing facilities that can produce drugs in bulk without patient-specific prescriptions. They are subject to FDA Current Good Manufacturing Practice (cGMP) standards. [1] For LDN, the relevant pathway is 503A because the preparation is patient-specific and dose-individualized. No 503B facility currently produces LDN in bulk for the commercial market.

Telehealth Prescribing of Low-Dose Naltrexone in Pennsylvania

Pennsylvania permits telehealth prescribing of low-dose naltrexone. A Pennsylvania-licensed physician, nurse practitioner, or physician assistant can conduct an initial evaluation via video or telephone and issue a valid LDN prescription that a 503A pharmacy can fill.

Pennsylvania Telehealth Law

Pennsylvania's telehealth law, Act 44 of 2021 (23 P.S. § 2717.1 et seq.), establishes that prescribers may use telehealth to evaluate and treat patients using the same standard of care as an in-person visit. The law applies to controlled substances with some restrictions, but naltrexone is not a controlled substance under the DEA schedule, which means telehealth prescribing of LDN carries no additional federal restrictions beyond standard prescribing requirements. [9]

How a Telehealth LDN Visit Works

A typical telehealth LDN visit takes 20 to 30 minutes. The clinician reviews the patient's diagnosis, medication history, and any contraindications (active opioid use is a contraindication because LDN would precipitate withdrawal). After the visit, the prescription is sent electronically to the patient's chosen 503A pharmacy. The pharmacy ships the medication directly to the patient's Pennsylvania address within two to five business days in most cases.

HealthRX clinicians follow a structured intake protocol that includes a review of the patient's current opioid use status, liver function history (naltrexone carries an FDA boxed warning for hepatotoxicity at high doses), [1] and prior treatment history before prescribing LDN via telehealth.

How to Pay the Least for Low-Dose Naltrexone in Pennsylvania

GoodRx and Discount Cards

GoodRx coupons apply to standard 50 mg naltrexone tablets at retail pharmacies, dropping the price to as low as $22 for a 30-day supply in some Pennsylvania locations. [3] GoodRx does not typically apply to compounded medications because compounders do not participate in the retail pharmacy network. For compounded LDN at $50/month, the cash price is already near the floor for this medication class.

90-Day Supply Discounts

Many Pennsylvania compounders offer a 10% to 15% discount on a 90-day supply versus three separate monthly fills. At $50/month, a 90-day supply might cost $127 to $135 rather than $150. That saves $15 to $23 over three months, or roughly $60 to $90 annually.

Patient Assistance Programs

Naltrexone's manufacturer (Teva Pharmaceuticals markets the branded 50 mg product, Vivitrol is the injectable form made by Alkermes) does not currently offer a patient assistance program specifically for low-dose compounded naltrexone. The NeedyMeds database lists income-based assistance programs for branded naltrexone products, which may be useful for patients whose providers are willing to try the standard tablet at a lower dose while titrating. [10]

Using an HSA or FSA

As noted above, an HSA or FSA covers LDN as a prescription medication. Patients who have access to these accounts should use them to reduce after-tax cost.

Clinical Evidence Supporting Low-Dose Naltrexone

Pennsylvania clinicians and patients asking about LDN should understand the evidence base. It is limited but growing.

Fibromyalgia Evidence

Younger and Mackey's 2009 pilot trial (N=10) showed a 30% reduction in fibromyalgia pain scores at 4.5 mg/night versus placebo (P<0.05). [2] Their 2013 randomized crossover trial (N=31) confirmed a statistically significant reduction in pain (28.8% reduction with LDN versus 18.0% with placebo, P<0.05), with the drug well tolerated and no serious adverse events. [11]

Multiple Sclerosis Evidence

A 2010 randomized controlled trial by Cree et al. (N=80) found that LDN 4.5 mg/night improved mental health quality-of-life scores in multiple sclerosis patients over 16 weeks (P<0.05). [12] Physical function scores did not differ significantly from placebo, indicating that LDN's benefit in MS may be primarily on fatigue and mood rather than neurologic function.

Crohn's Disease Evidence

Smith et al. (2011, N=40) conducted a randomized double-blind placebo-controlled trial of LDN in pediatric Crohn's disease. The response rate was 88% in the LDN group versus 40% in the placebo group (P<0.01). [13] A follow-up adult Crohn's trial by the same group found similar response patterns. These findings have contributed to growing interest in LDN among gastroenterologists, even without an FDA-approved indication.

What Guidelines Say

The American Academy of Pain Medicine has not issued a formal guideline on LDN as of early 2026. The American College of Rheumatology 2021 fibromyalgia guideline notes that naltrexone has insufficient evidence to recommend it conditionally, but stops short of recommending against it. [14] That language gives clinicians and patients room to consider LDN, especially when other treatments have failed.

Contraindications and Safety Considerations

LDN is generally well tolerated. The most common side effects are sleep disturbances and vivid dreams in the first two to four weeks, occurring in roughly 37% of new users in Younger's 2013 trial. [11] Taking the dose in the morning instead of at night resolves sleep disturbances for most patients.

Opioid Use Is an Absolute Contraindication

Any patient currently using opioid medications (prescription or otherwise) cannot take LDN without first discontinuing opioids for at least seven to ten days. LDN blocks opioid receptors and will precipitate withdrawal in an opioid-dependent patient. The FDA label for naltrexone 50 mg states this contraindication explicitly. [1]

Liver Function

Naltrexone at doses of 50 mg carries an FDA boxed warning for hepatocellular injury. At LDN doses (1.5 to 4.5 mg), the hepatotoxicity risk appears substantially lower, and no case reports of LDN-associated liver injury have been published in the peer-reviewed literature as of 2026. Clinicians ordering LDN should still obtain baseline liver function tests for patients with existing liver disease or heavy alcohol use.

Drug Interactions

Naltrexone interacts with opioid-containing medications including cough suppressants such as dextromethorphan and antidiarrheal agents containing loperamide. Patients should disclose all medications to their prescribing clinician before starting LDN.

Pennsylvania-Specific Resources for LDN Patients

The LDN Research Trust maintains a global database of clinicians who prescribe LDN, including several dozen Pennsylvania-licensed providers across Philadelphia, Pittsburgh, Harrisburg, and suburban counties. Pennsylvania patients can also use the HealthRX telehealth platform to connect with a licensed Pennsylvania clinician for an LDN evaluation without leaving home.

The Pennsylvania Department of Health's drug pricing transparency resources list compounding pharmacy licensing status, which patients can use to verify that a chosen pharmacy holds an active Pennsylvania State Board of Pharmacy license before sending a prescription.